ArticleVaccine2015
Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein.
Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluating the Immunogenicity of a RecombinantBiology · 2026Article
- Immunoinformatics method to design universal multi-epitope nanoparticle vaccine for TGEV S protein.Scientific reports · 2025Article
- Establishment of a pseudovirus neutralization assay for TGEV.Frontiers in immunology · 2025Article
- Prevention and Control of Swine Enteric Coronaviruses in China: A Review of Vaccine Development and Application.Vaccines · 2023Review
- Genetic comparison of transmissible gastroenteritis coronaviruses.Frontiers in veterinary science · 2023Article
- Generation of porcine PK-15 cells lacking the Ifnar1 or Stat2 gene to optimize the efficiency of viral isolation.PloS one · 2023Article
- Antigen epitopes of animal coronaviruses: a mini-review.Animal diseases · 2023Review
- Rabbit hemorrhagic disease virus VP60 protein expressed in recombinant swinepox virus self-assembles into virus-like particles with strong immunogenicity in rabbits.Frontiers in microbiology · 2022Article
- Porcine deltacoronavirus and its prevalence in China: a review of epidemiology, evolution, and vaccine development.Archives of virology · 2021Review
- Evolution, Interspecies Transmission, and Zoonotic Significance of Animal Coronaviruses.Frontiers in veterinary science · 2021Review
- Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine.Virology journal · 2020Article
- Vaccination against coronaviruses in domestic animals.Vaccine · 2020Review
- Swinepox virus vector-based vaccines: attenuation and biosafety assessments following subcutaneous prick inoculation.Veterinary research · 2018Article
- Efficacy and immunogenicity of recombinant swinepox virus expressing the truncated S protein of a novel isolate of porcine epidemic diarrhea virus.Archives of virology · 2017Article
- Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses.Veterinary microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the possibility of developing a vaccine against transmissible gastroenteritis virus (TGEV) infection, a recombinant swinepox virus (rSPV-SA) expressing a TGEV protective antigen has been constructed. Immune responses and protection efficacy of the vaccination vector were assessed in both mice and pig models. An indirect ELISA assay suggested that when mice were vaccinated with rSPV-SA, the level of IgG against TGEV was enhanced dramatically. The cytokine assays were employed and the results indicated that both the Th1-type and Th2-type cytokine levels raised after vaccination with rSPV-SA in mice models. Results from the passive immunity protection test of new born piglets demonstrated that the recombinant live-vector vaccine, rSPV-SA, could 100% protect piglets from the SPV infection, and there was no significant clinical symptom in the rSPV-SA treatment group during this experiment. The data suggest that the novel recombinant swinepox virus is a potential vaccine against TGEV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.